Market Access, Regulatory and Clinical Trial Experts in Europe
Pharma Design is a small service provider with a network of specialised consultants.
Core Services
- Strategic and Regulatory advice
- Marketing Applications, Scientific Advice, Paediatric Advice
- Orphan Designation
- Paediatric Plan and PDCO interaction
- Clinical Trial Design and CTA submission (EU, UK, Switzerland, Israel)
- Clinical Safety & Pharmacovigilance (DSUR, PSUR, RMP submission)
- Establishment of European subsidiaries, legal entities, headquarters, management teams
Our Services Are Highly Competitive
Pharmacovigilance
Our PV services covering your products in Europe, including EU, UK, Switzerland.
Regulatory Consulting
Choose our Regulatory Affairs strategic services for your products or have our specialised consultants outsourced to your team.
Market Access
Let us help you establish legal entity in Europe and prepare for Market Launch.
Recent Articles
-
MHRA Signals Major Overhaul of Rare Disease Regulatory Framework: Faster Paths to UK Approval in 2026
On 2 November 2025, MHRA published a pivotal position paper outlining a comprehensive overhaul of the regulatory framework for rare disease therapies in the UK.…
-
EMA’s PRIME Scheme vs. MHRA’s ILAP
Comparative Analysis: EMA’s PRIME Scheme vs. MHRA’s ILAP Navigating Accelerated Pathways for Innovative Medicines in the EU and UK The European Medicines Agency’s (EMA) PRIority…
News and Updates
-
MHRA’s New Guidance on Non-Standard Trial Designs: Unlocking Flexibility for UK CTIMPs
On October 15, 2025, the Medicines and Healthcare products Regulatory Agency (MHRA) released draft guidance on non-standard Clinical Trials of Investigational Medicinal Products (CTIMPs), marking…